AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024
Hand-out
Press Releases
AbelZeta Pharma, Inc.  
November 16, 2024

AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024

Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy targeting LN and SLE

avatar profile Olean Times Herald

Olean Times Herald


Local & Social